| Company Name: | Protalix BioTherapeutics, Incorporated | | Ticker Symbol: | PLX | | | WWW Address: | www.protalix.com | | CEO: | Dr. David Aviezer, Ph.D. | | No. of Employees: | 138 | | Common Issue Type: | CS | | Business Description: | The Company & its wholly-owned subsidiary, Protalix Ltd. operate as biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company's proprietary ProCellExtm protein expression sys
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 10.01 |  -0.06 | 9.53 | 10.04 | 10.07 | 10.09 | 9.71 | 680852 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 773.8 | 77.3 | 1.51 | -0.30 | 0.00 | 0.0 | 0.0 | 12.50 - 0.96 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 10.01 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 773.4 | mil |
| Latest Shares Outstanding | 77.3 | mil |
| Earnings pS (EPS) | -0.30 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 0 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 37.2 | mil |
| Float as % of Shares Outstanding | 48.6 | % |
| Foreign Sales | 0 | mil |
| Domestic Sales | 0 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 639.90 | % |
| Research & Devlopment (R&D) as % of Revenue | 2,160.80 | % |
| Gross Profit Margin | 0.0 | % |
| EBITDA Margin | 0.0 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 0.0 | % |
| Return on Assets (ROA) | -60.5 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -76.7 | % |
| Current Ratio | 3.7 | |
| Leverage Ratio (Assets/Equity) | 1.3 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | 0.24 | $ |
| Cash pS | 0.29 | $ |
| Book-Value pS | 0.39 | $ |
| Tangible Book-Value pS | 0.39 | $ |
| Cash Flow pS | -0.28 | $ |
| Free Cash Flow pS | -0.30 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 25.72 | |
| Price/Tangible Book Ratio | 25.72 | |
| Price/Cash Flow | -36.3 | |
| Price/Free Cash Flow | -33.2 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -6.5 | 94 | 10,790 | 41,305 |
| 4 Weeks | 12.50 | 9.00 | 8.44 | 18.6 | 117 | 9,648 | 192,959 |
| 13 Weeks | 12.50 | 5.88 | 6.07 | 64.9 | 155 | 7,277 | 465,740 |
| 26 Weeks | 12.50 | 3.58 | 3.67 | 172.8 | 222 | 5,383 | 683,637 |
| 52 Weeks | 12.50 | 0.96 | 1.20 | 734.2 | 611 | 3,132 | 786,103 |
| YTD | 12.50 | 1.74 | - | 444.0 | 450 | 3,334 | 750,208 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 10.31 | 10.79 | 9.20 | 6.43 | 5.36 | 1.51 | 1.97 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 0.00 | 0.0 | 0.00 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 0.00 | NA | 0.00 |
| R&D | 0.00 | NA | 0.00 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 0.0 | 0.0 | 0.0 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | -0.01 | 0.01 | 0.03 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 74.52 |
| Current Ratio | 7.9 |
| Quick Ratio (Acid Test) | 7.9 |
| Liquidity Ratio (Cash) | 7.71 |
| Receivables Turnover | 0.0 |
| Average Collection Period | 0 |
| Working Capital/Equity | 85.4 |
| Working Capital pS | 0.50 |
| Cash-Flow pS | -0.28 |
| Free Cash-Flow pS | -0.26 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 70.61 |
| Financial Leverage Ratio (Assets/Equity) | 1.1 |
| Debt Ratio | 12.7 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 2.1 |
| LT Debt/Total Liabilities | 0.0 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 0.00 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 4.39 |
| Tobin's Q Ratio | 15.22 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -32.24 |
| Enterprise Value (EV)/Free Cash Flow | -37.70 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 25.72 |
| Price/Book Ratio - LTM | 25.72 |
| Price/Cash Flow Ratio | -36.3 |
| Price/Free Cash Flow Ratio - LTM | -33.2 |
| Price/Sales Ratio | 931.84 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 0.07 |
| Tangible Book Value pS - LTM | 0.39 |
| Book Value pS - LTM | 0.39 |
| Capital Invested pS | 0.57 |
| Cash pS - LTM | 0.29 |
| Cash Flow pS - LTM | -0.28 |
| Free Cash Flow pS - LTM | -0.30 |
| Earnings pS (EPS) | -0.30 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 0.00 |
| Free Cash Flow Margin 5YEAR AVG | 0.00 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | 0.00 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.00 |
| Return on Capital Invested (ROCI) | -50.5 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -40.8 |
| Assets Productivity | 0.00 |
| Return on Assets (ROA) | -44.1 |
| Return on Assets (ROA) - 5YEAR AVRG. | -37.0 |
| Gross Profit Margin | 0.0 |
| Gross Profit Margin - 5YEAR AVRG. | 0.0 |
| EBITDA Margin - LTM | 0.0 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 0.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 0 |
| Revenue per Employee | 0 |
| Net Income per Employee | -162,420 |
| Average Collection Period | 0 |
| Receivables Turnover | 0.0 |
| Day's Inventory Turnover Ratio | 0 |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 0.00 |
| Assets/Revenue | 0.00 |
| Net Working Capital Turnover | 0.00 |
| Fixed Assets Turnover | 0.00 |
| Total Assets Turnover | 0.0 |
| Revenue per $ Cash | 0.00 |
| Revenue per $ Plant | 0.00 |
| Revenue per $ Common Equity | 0.00 |
| Revenue per $ Capital Invested | 0.00 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 0.0 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 0.0 |
| Research & Devlopment (R&D) as % of Revenue | 0.0 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 0.0 |
|
|  
|
| |
 |  |